Literature DB >> 8462027

Long-term follow-up of neoadjuvant chemotherapy with 5-fluorouracil and cisplatin with surgical resection and possible postoperative radiotherapy and/or chemotherapy in squamous cell carcinoma of the esophagus.

R W Carey1, A D Hilgenberg, E W Wilkins, N C Choi, D J Mathisen, H C Grillo, J C Wain, D L Logan, C Bromberg.   

Abstract

Seventy patients with local squamous cell carcinoma of the esophagus were treated between 1981 and 1990 with preoperative chemotherapy, surgical resection, and possible postoperative radiation therapy and/or chemotherapy. Chemotherapy included two cycles of 5-fluorouracil (1000 mg/m2) by continuous intravenous infusion on days 1-4 and cisplatin (100 mg/m2) on day 4. Complete clinical response (CCR) was achieved in 28 (41%) patients, partial clinical response (PCR) in 17 (25%), and no response in 23 (34%). Fifty-five (81%) patients were resected, 6 (9%) were explored, and 7 (10%) were unable to have surgery. Microscopic analysis of 55 resected patients showed 50 (91%) with active tumor, 1 (2%) with necrotic tumor, and 4 (7%) with a pathological complete response to chemotherapy. Twenty-six of the 55 resected patients (47%) had no gross evidence of disease at the time of surgical inspection. Median overall survival was 21.86 months (range 2-107 months) for all patients and 26.71 months (range 2-107 months) for resected patients. Actuarial 5-year survival rate was 31% for all patients and 39% for resected patients. Prolonged survival correlates with complete clinical response to chemotherapy, low pathological stage of disease, and successful resection of the lesion.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8462027     DOI: 10.3109/07357909309024826

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  9 in total

1.  Phase II trial of 5-fluorouracil and low-dose cisplatin in patients with squamous cell carcinoma of the esophagus.

Authors:  H Sekiguchi; S Akiyama; M Fujiwara; H Nakamura; K Kondo; Y Kasai; K Ito; J Sakamoto; H Takagi
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

2.  Esophageal carcinoma: prognostic differences between squamous cell carcinoma and adenocarcinoma.

Authors:  Christophe Mariette; Laetitia Finzi; Guillaume Piessen; Isabelle Van Seuningen; Jean Pierre Triboulet
Journal:  World J Surg       Date:  2005-01       Impact factor: 3.352

3.  A pathological study of tumour regression in oesophageal adenocarcinoma treated with preoperative chemoradiotherapy.

Authors:  B Dunne; J V Reynolds; E Mulligan; A Kelly; M Griffin
Journal:  J Clin Pathol       Date:  2001-11       Impact factor: 3.411

Review 4.  Adjuvant therapies for cancer of the thoracic esophagus.

Authors:  T Nishihira; T Nakano; S Mori
Journal:  World J Surg       Date:  1994 May-Jun       Impact factor: 3.352

Review 5.  Multimodal treatment for squamous cell esophageal cancer.

Authors:  U Fink; H J Stein; H Wilke; J D Roder; J R Siewert
Journal:  World J Surg       Date:  1995 Mar-Apr       Impact factor: 3.352

6.  Intensive multimodality therapy for carcinoma of the esophagus and gastroesophageal junction.

Authors:  M K Ferguson; L B Reeder; P C Hoffman; D J Haraf; L C Drinkard; E E Vokes
Journal:  Ann Surg Oncol       Date:  1995-03       Impact factor: 5.344

7.  5-Fluorouracil and cisplatin therapy after palliative surgical resection of squamous cell carcinoma of the esophagus. A multicenter randomized trial. French Associations for Surgical Research.

Authors:  X Pouliquen; H Levard; J M Hay; K McGee; A Fingerhut; O Langlois-Zantin
Journal:  Ann Surg       Date:  1996-02       Impact factor: 12.969

8.  Emerging aspects of oesophageal and gastro-oesophageal junction cancer histopathology - an update for the surgical oncologist.

Authors:  Ewen A Griffiths; Susan A Pritchard; Nicholas P Mapstone; Ian M Welch
Journal:  World J Surg Oncol       Date:  2006-11-21       Impact factor: 2.754

Review 9.  Diagnosis and treatment of esophageal neoplasms.

Authors:  H Kato
Journal:  Jpn J Cancer Res       Date:  1995-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.